anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ethanol
Trial phase: Not Applicable
ATC code: D08AX08 | V03AB16 | V03AZ01
SMILES: CCO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.

Ethanol: 6% volume/volume ethanol in 0.45% saline solution.
Eligibility criteria:
Inclusion Criteria:

Patients aged 21-80 with paroxysmal atrial fibrillation (AF), supraventricular tachycardia, or undifferentiated palpitations who are to undergo either an elective ablation procedure (for AF, atrial flutter, atria tachycardia, atrial ventricular nodal reentrant tachycardia (AVNRT), or atrial ventricular reentrant tachycardia (AVRT)) or a diagnostic electrophysiology study in order to diagnose and treat their clinical arrhythmia at the University of California, San Francisco (UCSF) will be eligible for enrollment.

Exclusion criteria:

Patients will be excluded if they are not in normal sinus rhythm (i.e. in AF, atrial tachycardia, atrial flutter, or incessant AVNRT/AVRT) at the time of onset of the procedure, any history of substance abuse or alcoholism as determined by history, AUDIT questionnaire, or chart review, left ventricular ejection fraction <50%, inability to give informed consent, liver dysfunction (elevated aspartate aminotransferase , alanine aminotransferase, total bilirubin, or alkaline phosphatase >2x normal), clinical evidence of liver disease (enlarged liver, caput medusa, spider angiomas, or other signs of liver disease on exam), or pregnancy.
Intervention: ALBUTEROL
Trial phase: Phase 4
ATC code: R03AC02 | R03AK04 | R03AK13 | R03AL02 | R03CC02
SMILES: CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 442
Group description: Supervised asthma therapy in schools

Supervised asthma therapy in schools: Therapy observed daily in school. Asthma education by American Lung Association
Eligibility criteria:
Inclusion Criteria:

A child with asthma attending a Tucson Unified School District elementary school selected for the study.

Exclusion Criteria:

No asthma.
Not attending a Tucson Unified School District elementary school selected for the study.
Intervention: Ketamine
Trial phase: Phase 4
ATC code: N01AX03 | N01AX14 | N06AX27
SMILES: CNC1(c2ccccc2Cl)CCCCC1=O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 80
Group description: Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
Eligibility criteria:
Inclusion Criteria:

Age 18-64
surgery: laparoscopic gastric reduction (gastric sleeve or gastric bypass)
ASA physical status classification I, II, III
Body Mass Index >35kg/m2
Fluent in English

Exclusion Criteria:

History of allergy to protocol medications
History of chronic opioid use
Pregnant patients
Drop out: Conversion to an open surgical route, patient or surgeon request.
Intervention: Ropivacaine
Trial phase: Not Applicable
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Group 1 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)

Ropivacaine: Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
Eligibility criteria:
Inclusion Criteria:

>18 year old,
ASA physical status classification system score (ASA) <=3
due to undergo elective unilateral hip arthroscopy by one surgeon Dr. Nho (Co-Principal Investigator)

Exclusion Criteria:

ASA physical status classification system score) (ASA) >3
history of opioid dependence or abuse
current chronic analgesic therapy (daily use =>20 mg oxycodone-equivalent opioid use within 2 weeks before surgery and duration of use >=4 weeks)
allergy to study medications (fentanyl and ropivicaine)
any neuromuscular deficit of the ipsilateral femoral nerve or quadriceps femoris muscle (including diabetic peripheral neuropathy)
diagnosis of hypertension and/or current treatment for hypertension
pregnancy
Intervention: Tranexamic acid
Trial phase: Phase 4
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 319
Group description: 10mg/kg tranexamic acid add in priming fluid, 10mg/kg single shot slowly when incision, followed by 2mg/(kg·h) infusion until the end of surgery

Tranexamic Acid: The loading doses were given in 15 minutes when incision.
Eligibility criteria:
Inclusion Criteria:

Noncyanotic congenital heart disease patients requiring cardiac surgeries under cardiopulmonary bypass
Rheumatic or recessive valvular disease patients requiring valvular repair or replacement under cardiopulmonary bypass
Coronary artery disease patients requiring coronary artery bypass graft under cardiopulmonary bypass

Exclusion Criteria:

Non-primary and emergency cardiac surgery
Disorder in coagulation function before surgery
Anemia before surgery
Definite liver and renal dysfunction
History of stroke
Pregnancy and lactation
Disabled in spirit or law
Fatal conditions such as cancer
Intervention: Tranexamic acid
Trial phase: Phase 4
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 318
Group description: 20mg/kg tranexamic acid add in priming fluid, 20mg/kg single shot slowly when incision, followed by 4mg/(kg·h) infusion until the end of surgery

Tranexamic Acid: The loading doses were given in 15 minutes when incision.
Eligibility criteria:
Inclusion Criteria:

Noncyanotic congenital heart disease patients requiring cardiac surgeries under cardiopulmonary bypass
Rheumatic or recessive valvular disease patients requiring valvular repair or replacement under cardiopulmonary bypass
Coronary artery disease patients requiring coronary artery bypass graft under cardiopulmonary bypass

Exclusion Criteria:

Non-primary and emergency cardiac surgery
Disorder in coagulation function before surgery
Anemia before surgery
Definite liver and renal dysfunction
History of stroke
Pregnancy and lactation
Disabled in spirit or law
Fatal conditions such as cancer
Intervention: Tranexamic acid
Trial phase: Phase 4
ATC code: B02AA02
SMILES: NC[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 318
Group description: 30mg/kg tranexamic acid add in priming fluid, 30mg/kg single shot slowly when incision, followed by 6mg/(kg·h) infusion until the end of surgery

Tranexamic Acid: The loading doses were given in 15 minutes when incision.
Eligibility criteria:
Inclusion Criteria:

Noncyanotic congenital heart disease patients requiring cardiac surgeries under cardiopulmonary bypass
Rheumatic or recessive valvular disease patients requiring valvular repair or replacement under cardiopulmonary bypass
Coronary artery disease patients requiring coronary artery bypass graft under cardiopulmonary bypass

Exclusion Criteria:

Non-primary and emergency cardiac surgery
Disorder in coagulation function before surgery
Anemia before surgery
Definite liver and renal dysfunction
History of stroke
Pregnancy and lactation
Disabled in spirit or law
Fatal conditions such as cancer
Intervention: Rivaroxaban
Trial phase: Not Applicable
ATC code: B01AF01
SMILES: O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing that was obtained by clinical team.

Apixaban, rivaroxaban, dabigatran, or edoxaban at standard dosing per FDA package insert for direct oral anticoagulants.

Heparin, Low-Molecular-Weight, or direct oral anticoagulants: Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team or either apixaban, rivaroxaban, dabigatran, edoxaban following a catheter related blood clot
Eligibility criteria:
Inclusion Criteria:

Upper extremity venous thrombosis associated with an indwelling catheter documented by ultrasound, CT or venography
Current hematologic or solid tumor malignancy undergoing chemotherapy, surgery, radiation or hormonal therapy for malignancy.
>18 years of age
Platelet count >50,000
Creatinine clearance >30 ml/min
Ability to provide informed consent

Exclusion Criteria:

Underlying medical condition or chemotherapy requiring long-term anticoagulation
Known underlying higher risk thrombophilias including antiphospholipid antibody syndrome, antithrombin, protein C or protein S deficiencies, or homozygosity or compound heterozygosity for prothrombin G20210A or Factor V R506Q mutations.
Inability to remove venous catheter
Anticipated replacement of central venous catheter within 3 months
Major bleeding or clinically relevant non-major bleeding in the preceding 60 days
Participation in another clinical trial that requires anticoagulation
Use of anticoagulant other than low-molecular weight heparin
Treatment with thrombolysis
Catheter removal >1 month prior to enrollment
Intervention: Prazosin
Trial phase: Phase 1
ATC code: C02CA01 | C02LE01
SMILES: COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.

Prazosin Hydrochloride: Gradual upward titration to 15mg/day for approximately three weeks.
Eligibility criteria:
Inclusion Criteria:

Healthy males and females of any ethnic origin between 19 and 45 years old

Exclusion Criteria:

Use of any illicit drugs in past 3 months prior to randomization and/or have a current or past diagnosis of drug abuse/dependence (including alcohol)
Current or past DSM-IV diagnosis of any Axis I psychiatric disorder
Major psychiatric illness and/or substance dependence in first order relatives
Current active or past suicidal ideation
Baseline systolic blood pressure outside the normal range
Current use of medications that could interact with prazosin (e.g. beta blockers, phosphodiesterasetype 5 inhibitors, indomethacin, verapamil, modafinil, clonidine)
Current use or use during the previous month of medication that may affect the CNS at the time of scanning (e.g. neuroleptics, bupropion)
Any significant abnormalities in baseline blood results (e.g. CBC, renal and hepatic indicators) or ECG readings that would preclude the use of prazosin
Pregnancy, trying to become pregnant or breastfeeding
Presence of metal objects in the body (e.g. some artificial joints, bone pins, surgical clips, skull plate, certain part of dental braces) or implanted electronic devices (e.g. cardiac pacemaker, neurostimulator), that preclude safe MR scanning
Claustrophobia
Participation in any nuclear medicine procedures that, including the dose received during participation in this study, will bring the total radiation dose over the currently approved guideline of 20mSv in a 12-month period
Cardiovascular or cerebrovascular diseases
History of or current neurological illnesses including seizure disorders, migraine, multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor
Abnormal body mass (defined as not within 20% of normal BMI
Learning disability, amnesia or other conditions that impede memory and attention
Intervention: Letrozole
Trial phase: Phase 4
ATC code: L02BG04
SMILES: N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: 5mg daily

Letrozole: Letrozole administered daily through the time of ovulation.
Eligibility criteria:
Inclusion Criteria:

Patient having regular menstrual cycles between 26-30 days
Ages 18-40
Patient must not be sexually active during the study period, or if so must be using a reliable form of non-hormonal birth control including tubal ligation or vasectomy, non-hormonal intrauterine contraceptive device (IUD), or condoms with spermicide.
Willing to participate in study and available for all monitoring visits.
IRB consent

Exclusion Criteria:

Patient must NOT have used hormonal contraception three months or less prior to study.
Irregular menstrual cycles (<26 days or >30 days within the last 6 months.
Untreated thyroid dysfunction or hyperprolactinemia
Pregnancy (current or within 3 months) or breastfeeding
Allergy or contraindication to letrozole
Intervention: Midazolam
Trial phase: Phase 3
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 31
Group description: 5 mg intranasal midazolam

USL261
Eligibility criteria:
Inclusion Criteria:

Subject has been admitted to the institution's EMU for seizure characterization or pre-surgical evaluation, or such admission is planned within 28 days
Subject body weight is ≥ 40 kg to ≤ 125 kg (inclusive)
Subject has an established diagnosis of partial or generalized epilepsy

Exclusion Criteria:

Subject has history of status epilepticus in the 6 months prior to Screening
Subject has a progressive neurological disorder such as brain tumor, demyelinating disease, or degenerative central nervous system (CNS) disease that is likely to progress in the next 12 months
Subject has respiratory failure (or is at risk for respiratory failure) or other severe cardiorespiratory disease with New York Heart Association Class III or IV functional status, or requires supplemental oxygen
Subject has acute narrow-angle glaucoma
Subject is receiving chronic benzodiazepine treatment (defined as an average of ≥ 4 administrations per week) and cannot safely withdraw from such treatment within the washout period prior to treatment
Intervention: Naltrexone
Trial phase: Phase 4
ATC code: A08AA62 | N02AA56 | N07BB04
SMILES: [H][C@@]12Oc3c(O)ccc4c3[C@@]13CCN(CC1CC1)[C@]([H])(C4)[C@]3(O)CCC2=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 59
Group description: Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.

Extended-Release Naltrexone: Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
Eligibility criteria:
Due to the nature of this study, which includes both randomized arms (XR-NTX and enhanced TAU) as well as a non-randomized observational arm (methadone treatment group, MTP) there are separate Inclusion/Exclusion criteria for those randomized vs. Non-Randomized, detailed below.

Randomized Arms (XR-NTX, ETAU)

Inclusion Criteria:

Adults >18yo incarcerated in NYC jails with known release dates.
DSM-V criteria for current opioid use disorder (DSM-IV opioid dependence).
Not currently in or planning to pursue agonist (methadone, buprenorphine) treatment at release.
Currently opioid free by history ('detoxed') and with a negative urine for all opioids.
General good health as determined by medical evaluation.

Exclusion Criteria:

Pregnancy, lactation, or planning conception.
Active medical illness (i.e., severe liver disease, congestive heart failure) precluding safe participation.
Untreated or poorly controlled psychiatric disorder precluding safe participation.
History of allergic reaction to naltrexone.
Current chronic pain condition treated with opioids.

Non-Randomized Arm (MTP) Inclusion Criteria

Adults >18yo incarcerated in NYC jails with known release dates.
DSM-V criteria for current opioid use disorder (DSM-IV opioid dependence).
Currently receiving regular methadone maintenance treatment through KEEP.
General good health as determined by medical evaluation.

Exclusion Criteria

Pregnancy, lactation, or planning conception.
Active medical illness (i.e., severe liver disease, congestive heart failure) precluding safe participation.
Untreated or poorly controlled psychiatric disorder precluding safe participation.
In community methadone treatment program at the time of most recent arrest.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: General anesthesia combined with thoracic epidural 0.9% normal saline 8ml
Eligibility criteria:
Inclusion Criteria:

Surgery for thoracotomies, BMI: 18-25 Kg/m2, American Society of Anesthesiologists(ASA) classification I or II.

Exclusion Criteria:

liver or kidney disease, alcohol dependence, take sedative recently, contraindications for epidural anesthesia.
Intervention: Lidocaine
Trial phase: Phase 4
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: General anesthesia combined with thoracic epidural 1% lidocaine 8ml
Eligibility criteria:
Inclusion Criteria:

Surgery for thoracotomies, BMI: 18-25 Kg/m2, American Society of Anesthesiologists(ASA) classification I or II.

Exclusion Criteria:

liver or kidney disease, alcohol dependence, take sedative recently, contraindications for epidural anesthesia.
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: General anesthesia combined with thoracic epidural 0.25% bupivacaine 8ml
Eligibility criteria:
Inclusion Criteria:

Surgery for thoracotomies, BMI: 18-25 Kg/m2, American Society of Anesthesiologists(ASA) classification I or II.

Exclusion Criteria:

liver or kidney disease, alcohol dependence, take sedative recently, contraindications for epidural anesthesia.
Intervention: Ropivacaine
Trial phase: Phase 4
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 80
Group description: General anesthesia combined with thoracic epidural 0.3% ropivacaine 8ml
Eligibility criteria:
Inclusion Criteria:

Surgery for thoracotomies, BMI: 18-25 Kg/m2, American Society of Anesthesiologists(ASA) classification I or II.

Exclusion Criteria:

liver or kidney disease, alcohol dependence, take sedative recently, contraindications for epidural anesthesia.
Intervention: OC-459
Trial phase: Phase 2
SMILES: Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 70
Group description: 50 mg orally once a day

OC000459: CRTH2 inhibitor
Eligibility criteria:
Inclusion Criteria:

Atopic dermatitis as defined by a score of at least 9 on the Nottingham Eczema Severity Score, stratified into moderate (score 9 to 11 inclusive) and severe (score 12 to 15 inclusive) disease.
Fully documented history of the use of topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI). Subjects without a fully documented history will be excluded from the study.
Male and female subjects with moderate to severe atopic dermatitis treated with by TCS and/or TCI (with or without emollients) at the time of screening and over the previous month.
Subjects must have had at least 1 AD flare in the previous 6 months.

Exclusion Criteria:

Receipt of any forbidden medication including over the counter preparations and herbal medicines within 14 days of the first dosing day with the exception of paracetamol up to a maximum of 2g daily.
Use of systemic steroids within 4 weeks of the screening visit, light therapy or immunosuppressants within 2 months of the screening visit.
Use of NSAIDs.
Subjects initially diagnosed with AD aged 2 years or over will be excluded unless they have either coexisting or a history of asthma and/or allergic rhinoconjunctivitis.
Subjects with contact dermatitis will be excluded.

Subjects with acute skin infection or acute disease flares. Subjects with active flares during the screening to randomisation period (visits 1 to 2) may be managed according to normal clinical practice and be rescreened once their flares are no longer active.

-
Intervention: OC-459
Trial phase: Phase 2
SMILES: Cc1c(Cc2ccc3ccccc3n2)c2cc(F)ccc2n1CC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 71
Group description: Orally once a day
Eligibility criteria:
Inclusion Criteria:

Atopic dermatitis as defined by a score of at least 9 on the Nottingham Eczema Severity Score, stratified into moderate (score 9 to 11 inclusive) and severe (score 12 to 15 inclusive) disease.
Fully documented history of the use of topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI). Subjects without a fully documented history will be excluded from the study.
Male and female subjects with moderate to severe atopic dermatitis treated with by TCS and/or TCI (with or without emollients) at the time of screening and over the previous month.
Subjects must have had at least 1 AD flare in the previous 6 months.

Exclusion Criteria:

Receipt of any forbidden medication including over the counter preparations and herbal medicines within 14 days of the first dosing day with the exception of paracetamol up to a maximum of 2g daily.
Use of systemic steroids within 4 weeks of the screening visit, light therapy or immunosuppressants within 2 months of the screening visit.
Use of NSAIDs.
Subjects initially diagnosed with AD aged 2 years or over will be excluded unless they have either coexisting or a history of asthma and/or allergic rhinoconjunctivitis.
Subjects with contact dermatitis will be excluded.

Subjects with acute skin infection or acute disease flares. Subjects with active flares during the screening to randomisation period (visits 1 to 2) may be managed according to normal clinical practice and be rescreened once their flares are no longer active.

-